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Summary
Purpose: To determine frequency, causes, and phenomenology of late seizure recur-
rence (SR) in patients with juvenile myoclonic epilepsy (JME) after remission of at
least 1 year.
Methods: Among 2722 epileptic patients from tertiary referral center, we retro-
spectively identified 105 patients (62 females; mean age 22.3  7.2 years) with an
established diagnosis of JME. All patients were treated with valproates (83.3%), or
lamotrigine, topiramate, phenobarbital, add-on clobazam, or combinations (16.2%).
Results: The median period of follow-up was 4.2  3.2 (range: 1—17) years. SR
occurred in 74 patients (70.5%) after median period of 2.4  3.2 years. Twenty-
two patients (29.7%) experienced myoclonic seizures (MS), 13 (17.7%) generalized
tonic—clonic seizures (GTCS), 37 (50%) a combination of MS and GTCS, and two (2.6%)
a combination of MS, GTCS and absence seizures. SR was associated most frequently
with sleep deprivation and AED withdrawal, and rarely with alcohol intake, drug
abuse, photostimulation, or menstruation. No provoking factors for SR were identified
in 31.1% and 45% of cases with MS and GTCS, respectively. The majority of patients
(59/74) had a single SR. A second SR occurred less frequently in patients in whom
valproate dosage was increased after the first SR ( p = 0.0048).
Conclusion: Late SR (mainly MS and GTCS) is detected frequently after prolonged
follow-up in patients with JME despite the use of best-known therapy, usually due to
AEDwithdrawal or erratic life style. Instead of futile efforts to persuade the patient to
conform to restrictive life style, it is probably more efficient to use initial higher doses
of AEDs.
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Juvenile myoclonic epilepsy (JME) is an age-related,
idiopathic, generalized epileptic syndrome present-
ing with bilateral, arrhythmic myoclonic seizures
(MS), generalized tonic—clonic seizures (GTCS),
and less frequently typical absence seizures
(AS).1,2 The most common factors that provoke
seizures are sleep deprivation, fatigue, excessive
alcohol intake, stress, photostimulation, and men-
struation.1,3—5 Valproate (VPA) is the drug of choice
that leads to complete remission of seizures in a
majority of patients.2,6,7 However, the frequency of
seizure recurrence (SR) during long-term follow-up,
despite VPA therapy, is not well known.
The aim of this study is to estimate frequency,
causes, and phenomenology of late SR in patients
with JME after at least a 1-year period of remission.Patients and methods
Among 2722 epileptic patients from the Department
of Epileptology of the Institute of Neurology CCS
(tertiary referral center) hospitalized between Jan-
uary 1987 and December 2003, we retrospectively
identified 137 patients with established diagnoses of
JME. We used the clinical charts archive and elec-
tronic database containing all data regarding the
first and all follow-up visits.
The diagnosis of JMEwasmade if patients fulfilled
all criteria according to Panayiotopoulos:4 (1) pre-
sence of single or repetitive, arrhythmic, irregular
MS, mainly occurring after awakening, predomi-
nantly in the arms; (2) normal neurological exam-
ination; (3) abnormal EEG findings presenting with
generalized SW discharges (focal or background
abnormalities were acceptable if other clinical cri-
teria were justified); (4) normal CT/MR scans. Exclu-
sion criteria were: (1) clinical and/or EEG evidence
of myoclonic jerks secondary to brain hypoxia,
metabolic diseases or other structural brain
abnormalities;8 (b) eyelid myoclonia with absence
seizures; (c) self-induced epilepsy; (d) pure forms of
photosensitive epilepsy; (e) poor drug compliance
and (f) without remission during the first year.
Twenty patients satisfied exclusion criteria (two
with eyelidmyocloniawith absences, fourwith struc-
tural brain abnormalities; nine with poor drug com-
pliance; five did not gain remission in the first year).
Tenpatientswere lost for follow-up, and twopatients
dropped out due to their refusal to comply with AED
regimen. Finally, 105 patients entered our cohort.
All patients were treated with antiepileptic drugs
(AED) and followed on 6 month scheduled visits for
at least 1 year. Additional visits were undertakenduring 1 week following SR. Compliance was verified
as reported by patients and by monitoring of plasma
drug levels at each visit. Authors performed all
follow-up visits, governed the therapy, determined
SR, and estimated provoking factors (PF).
We defined SR as appearance of any type of
solitary or repeated seizures that characterized
JME (MS, GTCS, AS). Single SR completed during
24 h and multiple SR recurred in more than one
24 h period. AED withdrawal was diagnosed if the
patient could confidently recall cessation in AED
intake for more than 3 days (five times plasma
half-life of VPA). Low plasma levels of AED (less
than 50% of the level obtained at the 1-year visit)
without clear anamnestic data of therapy cessation
were also considered as AED withdrawal. The defini-
tion of other PF (sleep deprivation, photostimula-
tion, menstruation, alcohol abuse, drug abuse, and
emotional stress) is obvious by its name.
After a follow-up period of at least 1 year, all
patients were divided into three groups according to
the association of SR with PF. Patients without any
SR during the follow-up period formed the first
group (No_SR). Patients who had SR associated with
obvious PF (usually with only one GTC in 6 months
and less than five MS or AS per month) formed
second group (PF_SR). Patients who had SR asso-
ciated with no obvious PF (usually with two or more
GTC in 6 months and more than five MS, or AS per
month) formed the third group (NoPF_SR). Our pol-
icy was not to change the AED or its dose in the first
two groups. However, in the third group, our policy
was either to increase the dose of the original AED,
to add another AED or to change therapy to different
AED. After the dose had been changed, patients
were followed for at least one additional year.
All patients signed forms of informed consent,
approved by the Ethical Committee. Chi square,
Mann—Whitney’s, Kruskal—Wallis’s test, Spearmen’s
coefficient of correlation, and descriptive statistics
were used when indicated.Results
After the introduction of AEDs, average period of
follow-up was 4.2  3.2 (range: 1—17) years. Demo-
graphic characteristics of the population, the num-
ber of patients with SR, and its timing are shown in
Tables 1 and 2.
During the first year, VPA was used as the first
monotherapy in 91 (83.8%) patients (dose range
250—2500 mg). Half of the patients treated with
VPA needed 500 mg or less and 3/4 needed
1000 mg or less for complete abolition of all sei-
zures. Lamotrigine (up to 400 mg), topiramate (up
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Table 1 Demographic and clinical characteristics of the patients and their epilepsy before the diagnosis of JME was
established
Total number of patients 105
Females 62
Males 43
Average age of patients at the moment of the first diagnosis of JME (years) 19.9  7.6 (11—51)
Average age of patients at the moment of the first seizure of any type (years) 16.8  6.3 (6—44)
Types of seizures in patients with established JME
Isolated MS 10 (9.5%)
MS + AS 3 (2.9%)
MS + GTCS 88 (88.3%)
MS + GTCS + AS 4 (3.8%)
Table 2 Frequency of seizure recurrence (SR) after the institution of AEDs
No. (%) Average time  S.D. in years
to recurrence (range)
Number of patients with SR
Recurrence of any seizure type 74 100 2.4  3.2 (1.1—17)
Recurrence of MS only 22 29.7 2.6  3.4 (1.1—17)
Recurrence of the combination of MS and GTCS 37 50 2.7 (1.1—5)
Recurrence GTCS only 13 17.7 4.5  4.6 (1.1—16)
Recurrence of MS and AS 1 1.3 1.8 (1.1—17)
Recurrence of MS, GTCS and AS 1 1.3 1.8 (0—17)
Number of patients with SR during particular periods
No. of patients with recurrence between 1.1 and 2 years 16 21.6 1.5 (1.1—1.9)
No. of patients with recurrence between 2.1 and 3 years
( p = 0.00009)
38 51.4 2.4 (2.1—2.9)
No. of patients with recurrence after 3.1 years 20 27 6.2 (3.1—17)
Number of patients with single or multiple recurred GTCS 51 100
No. of patients with single GTCS, with/without MS 43 84.3
No of patients with multiple single GTCS, with/without MS 4 7.8
No. of patients with serial GTCS (>2 GTCS in 24 h) 4 7.8to 400 mg), phenobarbital (up to 100 mg), clobazam
(up to 30 mg), or combinations were used in 16.2% of
patients for variety of pragmatic reasons.
SR was associated most frequently with sleep
deprivation (in 46% with MS and 31.1% with GTCS)
and AED withdrawal (in 15.9% with MS and 15.6%
with GTCS). In 14 patients (18.9%) with AED with-
drawal (all of them already treated with VPA), SR
occurred in the form of GTCS (with or without MS) in
eight patients, and in the form of sole MS in six
patients. In all 14 patients, VPA was immediately
reintroduced, and no second SR occurred during the
remainder of follow-up.
Less frequently, alcohol intake, drug abuse,
photostimulation, or menstruation also provoked
seizures. Before therapy, EEG characteristics of
photosensitivity were found in 17 patients
(16.2%). However, photosensitivity was associated
with either MS or GTCS in only seven (6.7%) patients.After the start of the AED, no SR could be attributed
to photosensitivity.
No PF were identified in 31.1% of patients with MS
and 45% of patients with GTCS (group NoPF_SR). In
two out of four patients with AS, PF for SR went
unrecognized, while sleep deprivation in one, and
emotional and physical stress in another patient
were probable PF for SR.
In 36 out of 74 patients with SR (48.7%) obviously
associated with PF (PF_SR group), the daily dose of
AED remained unchanged. In this group, second SR
occurred in 14 out of 36 (38.9%) patients during the
rest of the observation period. In 38 out of 74
(51.3%) patients with SR not obviously associated
with PF (NoPF_SR group), the daily dose of AED (VPA
in all of them) was increased (250—750 mg of VPA
were added) or supplementary therapy was intro-
duced (lamotrigine was added to VPA in three
patients). A second SR occurred in only four
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follow-up. The difference between the PF_SR group
with the unchanged and the NoPF_SR group with
increased dose of VPA was statistically significant
( p = 0.0048), favoring the group with increased
dose.Discussion
The SR occurred in 70% of our patients after a
remission longer than 1 year, despite the best-
known therapy. Most frequently, SR occurred
between 2 and 3 years after AED initiation, probably
at the time when it appeared to patients that the
epilepsy was gone. It is reasonable to assume that
compliance to an AED regime was less strict, at least
in some patients.9 In the settings of regular and
adequate AED therapy, the high rate of SR observed
in our study has been rarely described previously,
although the period of follow-up was shorter.6 The
long period of follow-up in our study is the key point
that enabled the detection of late SR of GTCS even
after more than 5 years (17 years in a single case) of
regular AED therapy.
Approximately 1/10 of our patients had isolated
MS prior to AED therapy, and all were treated with
less than 750 mg of VPA. If any SR occurred, it was
exclusively in the form of MS, possibly implyingmore
benign course of JME in their cases.1,3,4,10
Detected PF for all seizure types at the onset of
JME and at the time of SR (our group PF_SR) were
very similar. Sleep deprivation was the most fre-
quent factor that provoked SR, especially GTCS. AED
withdrawal is the second most common but
obviously the most important factor that provoked
SR.
Although the prevalence of photosensitivity as PF
of seizures in JME is 25—42%, it occurred in less than
16% of our patients despite meticulous use of recom-
mended photostimulation techniques.11 A low fre-
quency (12%) of photosensitivity in our previous
report may lead to speculation that older age of
patients or ethnic difference may be a possible
explanation.12 Before therapy, seizures were asso-
ciated with photosensitivity in only 6.7% of patients;
upon use of VPA, it disappeared, although some
experienced SR provoked by other PF. This could
suggest that VPA therapy abolishes photosensitivity
more effectively than seizures.
It has been stated that the identification and
correction of common PF that provoke SR helps to
better control seizures in JME.4 However, it appears
that the ‘‘erratic’’ life style (especially of adoles-
cents) that could provoke seizure occurrence is
difficult to correct. Our results suggest that if theAED dosage is increased in patients with SR and no
obvious PF (NoPF_SR group), the probability of a
second SR is significantly diminished. This contrasts
with the finding that small doses of VPA (usually less
than 1000 mg) have prolonged and complete effect
against all seizures of JME.1,3,6 However, it is reason-
able to start with lower doses of VPA that may have
long-term efficacy in approximately 30% of patients
(our No_SR group). In a small number of patients
with SR due to AED withdrawal (up to 18% in our
group), alcohol, or drug abuse (PF_SR group), it is
probably not justified to increase VPA dose but to
improve the AED compliance. However, in the
majority of patients, SR occurs spontaneously, or
associated with milder PF for SR (‘‘erratic’’ life
style). Because the risk of SR in this group (NoPF_SR)
is higher, increasing the dose of AED is probably the
most convenient solution. However, chronic adverse
effects of AEDs may emerge13 and the period
between seizures may be quite long, which renders
the benefit from chronic exposure of patients to
higher doses of AEDs controversial.
In conclusion, it seems that the late SR equally in
the formofMSandGTCSoccurs frequently in patients
with JME despite the best-known therapy. A period of
follow-up longer than 1 year (probably of at least 3
years) is necessary to estimate seizure control in
patients with JME. PF for SR often remain unrecog-
nized, necessitating the application of a higher
dosage of AEDs, which opens questions regarding
the benign nature of this epileptic syndrome.References
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